Another foreign pharmaceutical company has been exposed to layoffs! Pharmaco: no!

In recent years, the trend of layoffs and resignations in the pharmaceutical industry is one after another According to the statistics of the insiders, since 2018, the total number of layoffs of famous multinational pharmaceutical companies such as Novartis, Pfizer, Sanofi and GSK has reached nearly 20000 With the disruptive impact of volume purchase on the industry, it took the lead in triggering a chain reaction in foreign pharmaceutical enterprises, and all levels of adjustment are in progress from sales to R & D At the end of last week, another news of layoffs of foreign pharmaceutical companies spread all over the pharmaceutical circle According to the news spread in the pharmaceutical circle, it was not only the medical representatives who were laid off, but also the RSM (Regional Manager) and regional manager who were not spared The industry believes that pharmaceutical companies, especially multinational pharmaceutical companies, are generally affected by the pharmaceutical environment and policies After all, their good days of "lying down to make money" have passed After the results of volume purchase come out, the drug promotion team (now it seems that it also includes drug R & D and production) will be affected as a whole, and the market adjustment is inevitable At the same time, under a series of policies, such as the accounting information quality inspection of 77 pharmaceutical enterprises launched jointly by the state health insurance bureau and the Ministry of finance, and the tax inspection carried out by the State Administration of Taxation, the pressure of marketing compliance is growing In addition, in 2019, under the influence of consistency evaluation, volume purchase and other policies, China's pharmaceutical enterprises are also changing from generic drugs to high-end generic drugs and innovative drugs, and personnel changes, especially high-end talent changes, have become the general trend According to incomplete statistics, from January 2019 to October, at least 90 executives resigned, including Novartis, Merck, Mercedes, Taiji group, Li Zhu group, Tianmu pharmaceutical, essence pharmaceutical and other well-known pharmaceutical companies at home and abroad.